News Novo Nordisk obesity drug linked to rare cause of sight loss The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.
News NHS cleared to use Novo Nordisk's long-acting growth hormone Novo Nordisk's long-acting injectable Sogroya has been backed for NHS use in young people with growth hormone deficiency.
News MHRA advises contraception for women taking 'skinny jabs' Women in the UK taking weight-loss injections have been warned by the MHRA that they should make sure they are using effective contraception.
News Novo Nordisk's dropping share price spells the end for CEO Novo Nordisk's chief executive Lars Fruergaard Jørgensen is stepping down by "mutual agreement" with the company's board.
News Novo makes fresh obesity play with $2.2bn Septerna deal A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.
News Digital support reduces GLP-1 dose needed for weight loss Combining weight-loss drugs with online patient support can achieve results that match the drugs given on their own, but with a much-reduced dose.